Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$307.80 USD

307.80
3,427,831

+6.66 (2.21%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $307.00 -0.80 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (175 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

LabCorp Partners OmniSeq to Grow in Immuno-Oncology Space

by Zacks Equity Research

LabCorp (LH) decides to distribute OmniSeq's molecular diagnostics assays in the United States and beyond to grow in immuno-oncology space.

    Zacks Equity Research

    Stryker (SYK) to Gain From Solid Portfolio and Acquisitions

    by Zacks Equity Research

    Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.

      Zacks Equity Research

      Accuray's Radixact Now Used by Boise Summit Cancer Center

      by Zacks Equity Research

      Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.

        Zacks Equity Research

        Globus Medical's Robotic Guidance System Gets FDA Approval

        by Zacks Equity Research

        Positive tidings on the regulatory front have favored Globus Medical (GMED) of late. The company's latest regulatory progress would lend it a competitive edge in the global niche space.

          Zacks Equity Research

          Cardiovascular Systems Unveils Favorable LIBERTY 360 Data

          by Zacks Equity Research

          LIBERTY 360 Study shows the importance of endovascular intervention in patients with Critical Limb Ischemia (CLI) to prevent amputation.

            Zacks Equity Research

            Anika (ANIK) Grows in Orthopedic Medicines on Positive Data

            by Zacks Equity Research

            Anika Therapeutics' (ANIK) data shows HYALOFAST as an effective treatment option for cartilage lesions, suitable to all age groups.

              Zacks Equity Research

              STERIS (STE) Banks on Organic Growth, Competition Intense

              by Zacks Equity Research

              STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.

                Zacks Equity Research

                Model N (MODN) Q3 Loss Narrower than Expected, Revenues Miss

                by Zacks Equity Research

                Model N (MODN) reported narrower-than-expected loss in the third quarter driven by better customer acquisition.

                  Zacks Equity Research

                  Is a Surprise in Store for Penumbra (PEN) in Q2 Earnings?

                  by Zacks Equity Research

                  Penumbra's (PEN) escalating costs and expenses may keep margins under pressure in the yet-to-be-reported second quarter.

                    Mark Vickery headshot

                    Top Stock Reports for Procter & Gamble, Altria & Bristol-Myers

                    by Mark Vickery

                    Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Altria (MO) and Bristol-Myers (BMY).